Everyone’s been talking about the drug semaglutide, used to treat Type 2 diabetes. It’s marketed under the brand names Ozempic, Wegovy, and now, Mounjaro. Are any of the drugmakers a buy?

Salesforce’s Successful Quarter

HP is Having Problems

Macy’s Misses the Mark

Diabetes Drugs Take Over

Biotech Frontrunners

Why is Pfizer Underperforming?

Semaglutide Risks

Biotech Stock Picks

What Higher Yields Mean for Retired ‘Bucket’ Investors

Read about topics from this episode.

Salesforce Earnings: Margins Shine As New Signs of Pressure Remove Some Luster

HP Earnings: Sales Remain Soft, Although Improvement Is on the Horizon; Shares Fairly Valued

Macy’s Earnings: Lowered Outlook on Waning Spending Overshadows Positives; Shares Undervalued

Novo Nordisk and Eli Lilly Lead Potential $60 Billion Obesity Drug Market; Valuations Look Rich

Obesity Drug Stocks: Time to Buy?

What to watch from Morningstar.

Double Trouble: How the Dot-Com and Tech Bubbles Compare

What to Do as Recession Fears Grip Investors

Just Where’s the U.S. Economy Headed?

Active ETFs Take Off –– 3 Ideas for Investors

Read what our team is writing:

Follow us on social media.

Ruth Saldanha on Twitter: @karishmaruth

Facebook: https://www.facebook.com/MorningstarInc/

Twitter: https://twitter.com/MorningstarInc

Instagram: https://www.instagram.com/morningstar...

LinkedIn: https://www.linkedin.com/company/5161/

Gain From the Weight-Loss Trend With These Stocks 20:19 Share

Investing Insights

Shownotes Transcript

Gain From the Weight-Loss Trend With These Stocks